Clinical trial · Interventional
Multipeptide Vaccine for Advanced Breast Cancer
A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer. The goals of the study are: 1. to test the safety of the combination of agents 2. to find out what effects the treatment has on advanced breast cancer
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Cancer of the Breast | Malignant Breast Neoplasm | ALIAS | 0.90 |
| Carcinoma, Ductal | Breast Ductal Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hTERT/Survivin Multi-Peptide Vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- hTERT/Survivin Multi-Peptide Vaccine
- interventionNames
- Biological: hTERT/Survivin Multi-Peptide Vaccine
Primary outcomes (1)
- measure
- Safety
- timeFrame
- Up to 30 days after the last vaccination
Secondary outcomes (1)
- measure
- Immunologic response
- timeFrame
- After 4th vaccination, then after every 3-4 vaccinations, and then every 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage IV breast cancer that has failed at least one conventional therapy for metastatic disease * HLA-A2 positive * Measurable or evaluable disease * ECOG performance status 0-1 * Negative contrast CT or MRI scan of the brain within 30 days of treatment * Negative pregnancy test within 14 days of treatment for women of childbearing potential Exclusion Criteria: * History of brain metastases within the last 4 years * The use of chemotherapy, radiation therapy, immunosuppressive drugs, systemic glucocorticoids, growth factors, or experimental therapy, and anti-coagulants within 14 days prior to treatment * Initiation of hormonal agent in the 30 days before treatment * Initiation of Herceptin in the 30 days prior to treatment. * History of bone marrow or stem cell transplantation * Pregnant or lactating
References
Publications (0)
Data not yet available